Login to Your Account

GSK Bulks Up Discovery Work in $99M Cellzome Acquisition

By Catherine Shaffer
Staff Writer

Wednesday, May 16, 2012
Cellzome AG, of Heidelberg, Germany, will soon become GlaxoSmithKline plc's newest platform technology asset, subsequent to the pharma's acquisition of all outstanding shares of Cellzome for £61 million (US$99 million) in cash. GSK currently owns 19.98 percent of Cellzome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription